Pharmacologic Properties of Venlafaxine
J Clin Psychiatry 1997;58(4):178 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Findling et al. (May 1996 issue) report on their study of
venlafaxine in adult ADHD. Their rationale for the research was
simply that venlafaxine is an antidepressant; the fact that the
medication and its metabolite, O-desmethylvenlafaxine (ODV),
are weak inhibitors of dopamine reuptake is not mentioned.
Even in the brief paragraph on the pharmacology of venlafaxine,
its dopaminergic property is not alluded to, although
there is a general statement that, like tricyclic antidepressants,
venlafaxine inhibits synaptic monoamine reuptake.